Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sopharma AD-Sofia's shares outstanding for the quarter that ended in Mar. 2026 was 528 Mil.
Sopharma AD-Sofia's quarterly shares outstanding
increased
from Dec. 2025 (526 Mil) to Mar. 2026 (528 Mil).
It means Sopharma AD-Sofiaissued new shares from Dec. 2025 to Mar. 2026 .
Sopharma AD-Sofia's annual shares outstanding
increased
from Dec. 2024 (166 Mil) to Dec. 2025 (526 Mil).
It means Sopharma AD-Sofiaissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Sopharma AD-Sofia Shares Outstanding (EOP) Related Terms
Sopharma AD-Sofia Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Shares Outstanding (EOP) Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Shares Outstanding (EOP) vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 528 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a Shares Outstanding (EOP) of 528 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Shares Outstanding (EOP) too high?
Sopharma AD-Sofia's current Shares Outstanding (EOP) is 528 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Shares Outstanding (EOP) compare to MCK and CAH?
Sopharma AD-Sofia's Shares Outstanding (EOP) of 528 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Distribution company?
A good Shares Outstanding (EOP) depends on the Medical Distribution industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Shares Outstanding (EOP) is 528 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.52, compared to a current price of zł7.70 — trading 43% below its estimated fair value. The current Shares Outstanding (EOP) is 528 Mil. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Shares Outstanding (EOP) is 528 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.70 is trading 43% below its estimated GF Value™ of zł13.52.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Shares Outstanding (EOP): 528 Mil
GF Value™: zł13.52 vs. price of zł7.70 (43% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
